This report describes and explains the biopharmaceutical contract manufacturing organization (CMO) market and covers 2018-2023, termed the historic period, and 2023-2028, 2033F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global biopharmaceutical contract manufacturing organization (CMO) market reached a value of nearly $21.7 billion in 2023, having grown at a compound annual growth rate (CAGR) of 14% since 2018. The market is expected to grow from $21.7 billion in 2023 to $41.4 billion in 2028 at a rate of 13.8%. The market is then expected to grow at a CAGR of 14.4% from 2028 and reach $81.2 billion in 2033.
Growth in the historic period resulted from the increase in the robustness of venture capital investments for the life science sector, rising preference for outsourcing and growth in pharmaceutical research and development (R&D) expenditure. Factors that negatively affected growth in the historic period were regulatory challenges.
Going forward, the rising prevalence of chronic diseases, increase in healthcare expenditure, growing prevalence of cancer and increase in biopharmaceutical development will drive the growth. Factor that could hinder the growth of the biopharmaceutical contract manufacturing organization (CMO) market in the future include high cost of API and drug development with threat of failure.
The biopharmaceutical contract manufacturing organization (CMO) market is segmented by product into biologics and biosimilars. The biologics market was the largest segment of the biopharmaceutical contract manufacturing organization (CMO) market segmented by product, accounting for 80.1% or $17.4 billion of the total in 2023. Going forward, the biosimilars segment is expected to be the fastest growing segment in the biopharmaceutical contract manufacturing organization (CMO) market segmented by product, at a CAGR of 15.4% during 2023-2028.
The biopharmaceutical contract manufacturing organization (CMO) market is segmented by source into mammalian and non-mammalian. The mammalian market was the largest segment of the biopharmaceutical contract manufacturing organization (CMO) market segmented by source, accounting for 60.2% or $13 billion of the total in 2023. Going forward, the non-mammalian segment is expected to be the fastest growing segment in the biopharmaceutical contract manufacturing organization (CMO) market segmented by source, at a CAGR of 14.8% during 2023-2028.
The biopharmaceutical contract manufacturing organization (CMO) market is segmented by service into manufacturing, fill and finish operations, analytical and QC (quality check) studies and packaging. The manufacturing market was the largest segment of the biopharmaceutical contract manufacturing organization (CMO) market segmented by service, accounting for 44.5% or $9.7 billion of the total in 2023. Going forward, the manufacturing segment is expected to be the fastest growing segment in the biopharmaceutical contract manufacturing organization (CMO) market segmented by service, at a CAGR of 14.8% during 2023-2028.
North America was the largest region in the biopharmaceutical contract manufacturing organization (CMO) market, accounting for 47.7% or $10.3 billion of the total in 2023. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the biopharmaceutical contract manufacturing organization (CMO) market will be Asia Pacific and South America where growth will be at CAGRs of 16.8% and 13.8% respectively. These will be followed by North America and Western Europe where the markets are expected to grow at CAGRs of 13% and 12.7% respectively.
The global biopharmaceutical contract manufacturing organization (CMO) market is fairly fragmented, with a large number of small players operating in the market. The top ten competitors in the market made up to 14.66% of the total market in 2022. Catalent Inc was the largest competitor with a 5.05% share of the market, followed by Cytiva with 4.18%, Rentschler Biopharma with 1.58%, Boehringer Ingelheim GmbH with 0.76%, AGC Biologics Inc with 0.66%, Lonza Group AG with 0.51%, Samsung Biologics Co Ltd with 0.49%, CordenPharma with 0.48%, Wuxi Biologics Co Ltd with 0.47% and Thermo Fisher Scientific Inc with 0.47%.
The top opportunities in the biopharmaceutical contract manufacturing organization (CMO) market segmented by product will arise in the biologics segment, which will gain $15.1 billion of global annual sales by 2028. The top opportunities in the biopharmaceutical contract manufacturing organization (CMO) market segmented by source will arise in the mammalian segment, which will gain $11.1 billion of global annual sales by 2028. The top opportunities in the biopharmaceutical contract manufacturing organization (CMO) market segmented by service will arise in the manufacturing segment, which will gain $9.6 billion of global annual sales by 2028. The biopharmaceutical contract manufacturing organization (CMO) market size will gain the most in the USA at $8 billion.
Market-trend-based strategies for the biopharmaceutical contract manufacturing organization (CMO) market include focus on increased merger and acquisition activities to streamline operations, focus on strategic partnerships and collaborations among market players to drive innovation and focus on growing investments to build new products and technologies.
Player-adopted strategies in the biopharmaceutical contract manufacturing organization (CMO) market include focus on enhancing its business capabilities through strategic acquisitions, focus on strengthening its operational capabilities through strategic partnerships and focus on enhancing its business capabilities through new projects.
To take advantage of the opportunities, the analyst recommends the biopharmaceutical contract manufacturing organization (CMO) companies to focus on biosimilars segment for growth, focus on strategic investments for expansion, expand in emerging markets, continue to focus on developed markets, focus on strategic partnerships and collaborations, focus on strategic mergers and acquisitions for expansion, provide competitively priced offerings, focus on value-based pricing strategies, participate in trade shows and events, focus on educational content marketing and focus on talent development for manufacturing excellence.
The global biopharmaceutical contract manufacturing organization (CMO) market reached a value of nearly $21.7 billion in 2023, having grown at a compound annual growth rate (CAGR) of 14% since 2018. The market is expected to grow from $21.7 billion in 2023 to $41.4 billion in 2028 at a rate of 13.8%. The market is then expected to grow at a CAGR of 14.4% from 2028 and reach $81.2 billion in 2033.
Growth in the historic period resulted from the increase in the robustness of venture capital investments for the life science sector, rising preference for outsourcing and growth in pharmaceutical research and development (R&D) expenditure. Factors that negatively affected growth in the historic period were regulatory challenges.
Going forward, the rising prevalence of chronic diseases, increase in healthcare expenditure, growing prevalence of cancer and increase in biopharmaceutical development will drive the growth. Factor that could hinder the growth of the biopharmaceutical contract manufacturing organization (CMO) market in the future include high cost of API and drug development with threat of failure.
The biopharmaceutical contract manufacturing organization (CMO) market is segmented by product into biologics and biosimilars. The biologics market was the largest segment of the biopharmaceutical contract manufacturing organization (CMO) market segmented by product, accounting for 80.1% or $17.4 billion of the total in 2023. Going forward, the biosimilars segment is expected to be the fastest growing segment in the biopharmaceutical contract manufacturing organization (CMO) market segmented by product, at a CAGR of 15.4% during 2023-2028.
The biopharmaceutical contract manufacturing organization (CMO) market is segmented by source into mammalian and non-mammalian. The mammalian market was the largest segment of the biopharmaceutical contract manufacturing organization (CMO) market segmented by source, accounting for 60.2% or $13 billion of the total in 2023. Going forward, the non-mammalian segment is expected to be the fastest growing segment in the biopharmaceutical contract manufacturing organization (CMO) market segmented by source, at a CAGR of 14.8% during 2023-2028.
The biopharmaceutical contract manufacturing organization (CMO) market is segmented by service into manufacturing, fill and finish operations, analytical and QC (quality check) studies and packaging. The manufacturing market was the largest segment of the biopharmaceutical contract manufacturing organization (CMO) market segmented by service, accounting for 44.5% or $9.7 billion of the total in 2023. Going forward, the manufacturing segment is expected to be the fastest growing segment in the biopharmaceutical contract manufacturing organization (CMO) market segmented by service, at a CAGR of 14.8% during 2023-2028.
North America was the largest region in the biopharmaceutical contract manufacturing organization (CMO) market, accounting for 47.7% or $10.3 billion of the total in 2023. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the biopharmaceutical contract manufacturing organization (CMO) market will be Asia Pacific and South America where growth will be at CAGRs of 16.8% and 13.8% respectively. These will be followed by North America and Western Europe where the markets are expected to grow at CAGRs of 13% and 12.7% respectively.
The global biopharmaceutical contract manufacturing organization (CMO) market is fairly fragmented, with a large number of small players operating in the market. The top ten competitors in the market made up to 14.66% of the total market in 2022. Catalent Inc was the largest competitor with a 5.05% share of the market, followed by Cytiva with 4.18%, Rentschler Biopharma with 1.58%, Boehringer Ingelheim GmbH with 0.76%, AGC Biologics Inc with 0.66%, Lonza Group AG with 0.51%, Samsung Biologics Co Ltd with 0.49%, CordenPharma with 0.48%, Wuxi Biologics Co Ltd with 0.47% and Thermo Fisher Scientific Inc with 0.47%.
The top opportunities in the biopharmaceutical contract manufacturing organization (CMO) market segmented by product will arise in the biologics segment, which will gain $15.1 billion of global annual sales by 2028. The top opportunities in the biopharmaceutical contract manufacturing organization (CMO) market segmented by source will arise in the mammalian segment, which will gain $11.1 billion of global annual sales by 2028. The top opportunities in the biopharmaceutical contract manufacturing organization (CMO) market segmented by service will arise in the manufacturing segment, which will gain $9.6 billion of global annual sales by 2028. The biopharmaceutical contract manufacturing organization (CMO) market size will gain the most in the USA at $8 billion.
Market-trend-based strategies for the biopharmaceutical contract manufacturing organization (CMO) market include focus on increased merger and acquisition activities to streamline operations, focus on strategic partnerships and collaborations among market players to drive innovation and focus on growing investments to build new products and technologies.
Player-adopted strategies in the biopharmaceutical contract manufacturing organization (CMO) market include focus on enhancing its business capabilities through strategic acquisitions, focus on strengthening its operational capabilities through strategic partnerships and focus on enhancing its business capabilities through new projects.
To take advantage of the opportunities, the analyst recommends the biopharmaceutical contract manufacturing organization (CMO) companies to focus on biosimilars segment for growth, focus on strategic investments for expansion, expand in emerging markets, continue to focus on developed markets, focus on strategic partnerships and collaborations, focus on strategic mergers and acquisitions for expansion, provide competitively priced offerings, focus on value-based pricing strategies, participate in trade shows and events, focus on educational content marketing and focus on talent development for manufacturing excellence.
Table of Contents
1 Executive Summary
6 Market Characteristics
7 Major Market Trends
8 Biopharmaceutical Contract Manufacturing Organization (CMO) Market - Macro Economic Scenario
9 Global Market Size and Growth
10 Global Biopharmaceutical Contract Manufacturing Organization (CMO) Market
11 Biopharmaceutical Contract Manufacturing Organization (CMO) Market, Regional and Country Analysis
12 Asia-Pacific Market
13 Western Europe Market
14 Eastern Europe Market
15 North America Market
16 South America Market
17 Middle East Market
18 Africa Market
19 Competitive Landscape and Company Profiles
22 Key Mergers and Acquisitions
23 Opportunities and Strategies
24 Biopharmaceutical Contract Manufacturing Organization (CMO) Market, Conclusions and Recommendations
25 Appendix
Executive Summary
Biopharmaceutical Contract Manufacturing Organization (CMO) Global Market Opportunities and Strategies to 2033 provides the strategists; marketers and senior management with the critical information they need to assess the global biopharmaceutical contract manufacturing organization (CMO) market as it emerges from the COVID-19 shut down.Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description
Where is the largest and fastest-growing market for biopharmaceutical contract manufacturing organization (CMO)? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The biopharmaceutical contract manufacturing organization (CMO) market global report answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider biopharmaceutical contract manufacturing organization (CMO) market; and compares it with other markets.
The report covers the following chapters:
- Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by product, by source and by service.
- Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Macro-Economic Scenario - The report provides an analysis of the impact of the Russia-Ukraine war, impact of the COVID-19 pandemic and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the biopharmaceutical contract manufacturing organization (CMO) market.
- Global Market Size and Growth - Global historic (2018-2023) and forecast (2023-2028, 2033F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional and Country Analysis - Historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison by region and country.
- Market Segmentation - Contains the market values (2018-2023) (2023-2028, 2033F) and analysis for each segment by product, by source and by service in the market. Historic (2018-2023) and forecast (2023-2028) and (2028-2033) market values and growth and market share comparison by region market.
- Regional Market Size and Growth - Regional market size (2023), historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major and Innovative Companies - Details on the company profiles of other major and innovative companies in the market.
- Competitive Benchmarking - Briefs on the financials comparison between major players in the market.
- Competitive Dashboard - Briefs on competitive dashboard of major players.
- Key Mergers and Acquisitions - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
- Market Opportunities and Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions and Recommendations - This section includes recommendations for biopharmaceutical contract manufacturing organization (CMO) providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Scope
Markets Covered:
1) by Product: Biologics; Biosimilars2) by Source: Mammalian; Non-Mammalian
3) by Service: Manufacturing; Fill and Finish Operations; Analytical and QC (Quality Check) Studies; Packaging.
Key Companies Mentioned: Catalent Inc; Cytiva; Rentschler Biopharma; Boehringer Ingelheim GmbH; AGC Biologics Inc
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Brazil; Canada; France; Germany; UK; Italy; Spain; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; biopharmaceutical contract manufacturing organization (CMO) indicators comparison.
Data Segmentation: Country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Catalent Inc
- Cytiva
- Rentschler Biopharma
- Boehringer Ingelheim GmbH
- AGC Biologics Inc
- Lonza Group AG
- Samsung Biologics Co Ltd
- CordenPharma
- Wuxi Biologics Co Ltd
- Thermo Fisher Scientific Inc
- 3SBio Inc
- Alphamab Oncology
- Xiamen Amoytop Biotech Co. Ltd
- Anhui Anke Biotechnology
- Beigene
- Aurobindo Pharma Ltd
- Dr. Reddy's Laboratories
- Cadila Pharmaceuticals
- Celltrion Inc
- GlaxoSmithKline Plc
- AstraZeneca Plc
- Accord Healthcare Ltd
- ASKA Biotech GmbH
- KBI Biopharma
- Fujifilm Diosynth Biotechnologies USA Inc
- AbbVie Inc
- Biogen Inc
- Bristol-Myers Squibb Co
- Eli Lilly and Company
- Gilead Sciences Inc
- Pfizer Inc
- BiotechTown (Brazil)
- Sinergium Biotech
- BioCruz
- Medifarma S.A
- Biofarma S.A
- Teva Pharmaceutical Industries Ltd
- Neopharm Israel
- Kamada Ltd
- Taro Pharmaceutical Industries Ltd
- Medison Pharmaceuticals
- Exeltis
- Sandoz
- UNICHEM GHANA LIMITED
- Kinapharma Limited
- Fresenius Kabi
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 277 |
| Published | May 2024 |
| Forecast Period | 2023 - 2033 |
| Estimated Market Value ( USD | $ 21.7 Billion |
| Forecasted Market Value ( USD | $ 81.2 Billion |
| Compound Annual Growth Rate | 14.1% |
| Regions Covered | Global |
